Literature DB >> 9037349

Molecular genetics of hereditary elliptocytosis and hereditary spherocytosis.

J Delaunay1, N Alloisio, L Morle, F Baklouti, N Dalla Venezia, P Maillet, R Wilmotte.   

Abstract

Red cells ow their mechanical properties, that is, their resistance and their elastic deformability, to a protein network that laminates the lipid bilayer and to proteins spanning the latter. All proteins are interconnected. Their structure, as well as the structure of the corresponding genes, will be outlined. Numerous mutations have allowed to reclassify hereditary elliptocytosis (HE) and poikilocytosis (HP), and, more recently, hereditary spherocytosis (HS) into well defined subsets of hereditary hemolytic anemias. HE stems from changes in the SPTA1, SPTB, EL1 and (exceptionally) GPYC genes that encode spectrin alpha- and beta- chains, protein 4.1 and glycophorin C/D, respectively. HS derives from altercations in the ANK1, EPB3 and ELB42 genes, encoding ankyrin, band 3 and protein 4.2, respectively, and also in the SPTA1 and SPTB genes. We will present a repertory of the known mutations. Innumerable polymorphisms will not be considered here, except for a few remarkable ones. Some general points must be stressed on. (a) Clinically conspicuous disorders are often the result of two alleles interacting in trans to one another. Whereas one allele causes moderate symptoms by itself, the other one is usually silent in the simple heterozygous (and exceptionally in the homozygous) state. As a result, the number of potentially pathogenic alleles is much more important than had been initially suspected. (b) The reduction or the loss of a protein within multiprotein assemblies are frequently encountered in red cell membrane genetic diseases; it leads to the disruption of the complexes with the possible disappearance of the other proteins than the mutated protein. (c) The above genes being also expressed in nonerythroid tissues, one starts finding multisyndromic conditions adding non-hematological manifestations to hemolysis. It is puzzling, though, that such situations are not more frequent. (d) In practice, the molecular diagnosis of HE and HS has reached a semi-routine stage that helps very much the paediatricians and haematologists.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9037349

Source DB:  PubMed          Journal:  Ann Genet        ISSN: 0003-3995


  7 in total

Review 1.  The molecular basis of disorders of the red cell membrane.

Authors:  M F McMullin
Journal:  J Clin Pathol       Date:  1999-04       Impact factor: 3.411

Review 2.  Computational Biomechanics of Human Red Blood Cells in Hematological Disorders.

Authors:  Xuejin Li; He Li; Hung-Yu Chang; George Lykotrafitis; George Em Karniadakis
Journal:  J Biomech Eng       Date:  2017-02-01       Impact factor: 2.097

Review 3.  Janus kinases and focal adhesion kinases play in the 4.1 band: a superfamily of band 4.1 domains important for cell structure and signal transduction.

Authors:  J A Girault; G Labesse; J P Mornon; I Callebaut
Journal:  Mol Med       Date:  1998-12       Impact factor: 6.354

Review 4.  Ankyrin protein networks in membrane formation and stabilization.

Authors:  Shane R Cunha; Peter J Mohler
Journal:  J Cell Mol Med       Date:  2009-10-16       Impact factor: 5.310

5.  Involvement of Band3 in the efflux of sphingosine 1-phosphate from erythrocytes.

Authors:  Makoto Kurano; Masako Nishikawa; Hiroyuki Kuma; Masahiro Jona; Yutaka Yatomi
Journal:  PLoS One       Date:  2017-05-11       Impact factor: 3.240

6.  Clinical course of 63 children with hereditary spherocytosis: a retrospective study.

Authors:  Maria Christina Lopes Araujo Oliveira; Rachel Aparecida Ferreira Fernandes; Carolina Lins Rodrigues; Daniela Aguiar Ribeiro; Maria Fernanda Giovanardi; Marcos Borato Viana
Journal:  Rev Bras Hematol Hemoter       Date:  2012

7.  Novel compound heterozygous SPTA1 mutations in a patient with hereditary elliptocytosis.

Authors:  Shiyue Ma; Jinqiu Qin; Aiqiu Wei; Xiaohong Li; Yuanyuan Qin; Lin Liao; Faquan Lin
Journal:  Mol Med Rep       Date:  2018-02-26       Impact factor: 2.952

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.